REG - Trellus Health PLC - Update on Funding & Suspension of Trading

Trellus HealthAnnouncement

08/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260508:nRSH5146Da&default-theme=true

RNS Number : 5146D  Trellus Health PLC  08 May 2026

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014 as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the
Company's obligations under Article 17 of MAR. Upon the publication of this
announcement, this inside information is now considered to be in the public
domain.

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Update on Funding

&

Suspension of Trading

 

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus
Elevate®, a digital platform that integrates data analytics with
personalised, scientifically proven resilience programmes and value-based
solutions to manage complex chronic conditions, stated on 13 April 2026 that
it had reduced its monthly cash burn to an average of c. $300k as of March
2026 and that, with a contract renewal, and a loan from a co-founder, it
expected its cash runway to extend into May 2026.

 

The Board remains supportive of the Company's commercial strategy and
continues to evaluate a range of potential funding options to further extend
the Company's cash runway. The Company has further extended its runway until
mid-June 2026 through additional cost-saving measures, including further
reductions in compensation and the renegotiation of certain vendor contracts
amongst other measures.

 

The Board is, however, mindful that it has not yet been successful in securing
long term funding. In addition, although the Convertible Loan Note Facility
provided by Alumni Capital LLC remains in place, utilisation continues to be
constrained by current market conditions.

 

Consequently, the Board has engaged corporate restructuring advisers to
protect stakeholders' interests, and the Board is now evaluating all options
including the sale of Trellus Health Inc., the Company's US subsidiary. Due to
the ongoing uncertainty regarding the Company's financial position, its
current limited working capital and the circumstances noted above, the Company
has requested that its shares are suspended from trading on AIM with effect
from 7.30 a.m. today.

 

Further announcements will be made as appropriate.

 

Enquiries:

 

 Trellus Health plc                                                                      https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder                                     Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)
 Philip Davies / Jalini Kalaravy / Samed Ethemi                Tel: +44 (0)20 7496 3000 303/

 Walbrook PR                   Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                           (mailto:trellus@walbrookpr.com)
 Lianne Applegarth /                                                               Mob: +44 (0)7584 391 303/
 Alice Woodings                                                                                                          +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

 

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEADSXEESKEAA



            Copyright 2019 Regulatory News Service, all rights reserved